Glycans as Possible Biomarkers in Diagnosis of Neurodegenerative Diseases

Glycosylation is one of the most significant and common protein modifications.Many clinical biopharmaceuticals today are also glycosylated. The resulting glycoproteinsmay have one or more glycan structures attached through N- or O-glycosidic bonds. Theprofiles of glycosylation can change with aging, as well as in conditions like Alzheimer’s,Parkinson’s, and other neurological disorders. This means that many glycoproteins couldserve as useful biomarkers for diagnosing diseases and tracking their progression. However,the role of glycosylation in the central nervous system is not well understood, even thoughit is quite prevalent. Future research will focus on creating detailed glycoprofiles fromdifferent body fluids and tissues and analysing this enormous amount of information byusing conventional methods with the help of artificial intelligence lately.